Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Lakewood-Amedex Biotherapeutics (LABT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lakewood-Amedex Biotherapeutics is the larger company by market cap ($1.9 million vs $1.1 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | LABT |
|---|---|---|
| Share price | $0.505 | $0.7835 |
| Market cap | $1.11M | $1.86M |
| 1-day change | -3.57% | -1.07% |
| P/E ratio (TTM) | 0.01 | — |
| EPS (TTM) | $63.74 | $-8.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $98.20 |
| 52-week low | $0.493 | $0.76 |
| Distance from 52-week high | -99.03% | -99.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1664.36% | +1431.59% |
| Average volume | 3.72M | 2.50M |
| Shares outstanding | 2.20M | 2.37M |
| Employees | 11 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Lakewood-Amedex Biotherapeutics
LABT stock →Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
BDRX vs LABT FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Lakewood-Amedex Biotherapeutics?
Lakewood-Amedex Biotherapeutics (LABT) is larger, with a market capitalization of $1.86M compared with $1.11M for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Are Biodexa Pharmaceuticals American Depositary Shs and Lakewood-Amedex Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.